NISSHA President Junya Suzuki: “We will continue carefully selected M&A” – Performance of acquired Shiga Pharmaceutical Co., Ltd. – Kyoto Shimbun Digital

News Highlights

NISSHA President Junya Suzuki announced a policy to continue carefully selected M&A. He specifically mentioned the smooth performance of Shiga Pharmaceutical Co., Ltd., acquired in 2023. The company aims to expand its business in the medical and healthcare fields by strengthening its pharmaceutical operations, suggesting that this acquisition is part of that strategy. NISSHA is clearly promoting strategic M&A with the goal of achieving synergy with existing businesses and creating new business opportunities.

M&A Medical Editorial Perspective

NISSHA’s acquisition of Shiga Pharmaceutical Co., Ltd. and its subsequent smooth performance serve as a prime example of the effectiveness of entering the medical and healthcare field from a different industry, particularly in the pharmaceutical domain through M&A. The background to President Suzuki’s statement about continuing “carefully selected M&A” likely stems from the recognition that not just scale expansion, but also alignment with corporate strategy and successful post-merger integration (PMI) are essential. For mid-sized and small pharmaceutical companies like Shiga Pharmaceutical Co., Ltd., M&A by a major corporation can bring benefits such as access to management resources, acceleration of research and development, and expansion of sales channels, making it a viable option for business succession. NISSHA’s strategy holds the potential to accelerate business succession and consolidation movements in the pharmaceutical industry.

Key Discussion Points from This News

• NISSHA signals full-scale entry into the pharmaceutical sector with the acquisition of Shiga Pharmaceutical Co., Ltd., drawing attention as a successful case of cross-industry M&A
• Continuation of “carefully selected M&A” reflects an emphasis on strategic alignment and successful PMI
• M&A by major corporations may offer a new path for business succession and growth for mid-sized and small pharmaceutical companies
• NISSHA’s strategy may influence future consolidation and integration movements in the pharmaceutical industry

Practical Questions Arising from This News

• What specific PMI measures did NISSHA implement after acquiring Shiga Pharmaceutical Co., Ltd. to improve its performance?
• Beyond the pharmaceutical field, what other medical and healthcare areas is NISSHA considering for future “carefully selected” M&A targets?
• What specific synergistic effects can a pharmaceutical company of Shiga Pharmaceutical Co., Ltd.’s size gain through M&A?

If You Feel “Should I Consult Too?”

If your clinic or company is facing challenges with a lack of successors or barriers to business expansion, NISSHA’s case demonstrates that third-party succession or business restructuring can be effective options. In particular, companies with expertise in specific areas, such as pharmaceuticals, have significant potential to gain new growth opportunities through M&A with major players from different industries. It would be a good opportunity to start considering, with experts, whether M&A can be a realistic solution for business continuity and development, by comparing your company’s current situation and future outlook.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. We handle consultations with strict confidentiality. Free consultations are available here.